ATS 2019 Virtual Final Program

The annual Clinical Year in Review symposia provides concise summaries of the most impactful clinical research publications related to specific clinical topics. Speakers are asked to conduct a literature review of the prior year’s scientific publications and develop a written summary of the top 20 articles and highlight 5 of the most important and influential publications on their topic in written format and during their talks at the International Conference Clinical Year in Review sessions. Chairing: V.E. Ortega, MD, PhD, ATSF, Winston Salem, NC J.S. Lee, MD, Aurora, CO P.A. Kritek, MD, EdM, Seattle, WA 9:15 Sepsis and Septic Shock C.W. Seymour, MD, MSc, Pittsburgh, PA 9:44 Health Disparities N. Thakur, MD, MPH, San Francisco, CA 10:13 COPD N.N. Hansel, MD, MPH, Baltimore, MD 10:42 Interventional Pulmonology M.R. Bowling, MD, Greenville, NC 11:11 MOC Questions BASIC • CLINICAL CLINICAL TOPICS IN PULMONARY MEDICINE CME Credits Available: 2 A2 THE NEW ENGLAND JOURNAL OF MEDICINE AND JAMA. DISCUSSION ON THE EDGE: REPORTS OF RECENTLY PUBLISHED PULMONARY RESEARCH 9:15 a.m. - 11:15 a.m. KBHCCD Room D163/D165/D170/D172 (Level 1) This session will provide a forum for attendees to interact with the authors and editors about papers published in the New England Journal of Medicine and JAMA and. Papers presented will be recent publications, selected by the editors, to be of significant importance to the field of pulmonary medicine. Attendees will have the opportunity to hear presentations directly from the author and address questions to both the authors and editors. The discussion is intended to provide a unique insight into these papers, the selection process, and how the research applies directly to the field of pulmonary medicine. Chairing: J. Drazen, MD, Boston, MA G. T. O'Connor, MD, Boston, MA Speakers and Talks to be Announced. CLINICAL • TRANSLATIONAL CLINICAL TOPICS IN PULMONARY MEDICINE CME Credits Available: 2 A3 WHEN THERE IS NO RIGHT ANSWER: A PRO/CON DEBATE ON CONTROVERSIES IN ILD Assemblies on Clinical Problems; Behavioral Science and Health Services Research 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom C Three-Four (Level 2) Target Audience Clinicians and researchers with a focus on interstitial lung disease, trainees. Objectives At the conclusion of this session, the participant will be able to: • more appropriately refer patients with scleroderma, IPF, and rapidly progressive ILD for appropriate, evidence-based therapies; • adopt a patient-centered approach when discussing risks and benefits of therapies in patients with ILD, especially the use of anti-fibrotics in the frail and/or elderly; • highlight controversy surrounding the implementation of IPAF clinical criteria and the need for a single framework with which to evaluate patients with autoimmune features and ILD. The evaluation and management of interstitial lung disease is an evolving topic where clinicians are often left without a clear “right” answer. We will use the popular pro/con debate format to engage the audience in four areas of current controversy in the field including whether patients with scleroderma should undergo lung transplantation, if elderly patients with idiopathic pulmonary fibrosis (IPF) should be treated with anti-fibrotic therapy, whether patients with rapidly progressive interstitial lung disease should be treated with extracorporeal membrane oxygenation (ECMO), and whether interstitial pneumonia with autoimmune features (IPAF) is a distinct clinical entity and should be treated as such. Chairing: S.M. Bhorade, MD, Chicago, IL R. Jablonski, MD, Chicago, IL 9:15 PRO: Lung Transplant Is a Viable Treatment Option for Scleroderma M.M. Crespo, MD, Philadelphia, PA 9:27 CON: Other Options Should Be Explored for Management of Scleroderma Lung Disease R. Jablonski, MD, Chicago, IL 9:39 Rebuttal M.M. Crespo, MD, Philadelphia, PA 9:45 PRO: All Patients with IPF Should Receive Anti-Fibrotic Therapy T.M. Maher, MD, MSc, PhD, London, United Kingdom 9:57 CON: All Patients with IPF Should Not Receive Anti-Fibrotic Therapy S.D. Nathan, MD, Falls Church, VA 10:09 Rebuttal T.M. Maher, MD, MSc, PhD, London, United Kingdom ATS 2019 • Dallas, TX SUNDAY • MAY 19 25 SUNDAY MORNING